Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19 (SWITCH-COVID)

University of Sao Paulo

Status and phase

Terminated

Phase 3

Phase 2

Conditions

Angiotensin II Receptor Antagonist Adverse Reaction

Covid19

Treatments

Drug: Renin-angiotensin system inhibitors

Study type

Interventional

Funder types

Other

Identifiers

NCT04493359

33575220.9.0000.0068

Details and patient eligibility

About

The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.

Full description

Patients eligible for the study, after signing informed consent will be randomized 1:1 for maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy for other classes according to a pre-specified protocol.

Patients are going to be followed during hospital stay for evaluation of clinical endpoints. Also blood and urine samples will be acquired for evaluation of renin-angiotensin system activation.

Enrollment

18 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Hypertension in use of renin-angiotensin system inhibitors
Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical presentation and chest CT.
Symptoms onset < 96h
Need for hospitalization

Exclusion criteria

Heart failure
Previous cerebrovascular disease
Previous myocardial infarction
Blood pressure > 180 x 100 mmHg
Need for 3 or more anti-hypertensive classes
Use os spironolactone
Severe pulmonary disease
Contraindication for using other anti-hypertensive classes (calcium channel blockers, hydralazine, diuretics or nitrates)